Estimating the costs and cost-effectiveness of HIV self-testing among men who have sex with men, United States

Ram K Shrestha1,8, Pollyanna R Chavez1,6, Meredith Noble2, Stephanie L Sansom1, Patrick S Sullivan3,8, Jonathan H Mermin1 and Robin J MacGowan1

§Corresponding author: Ram K Shrestha, Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA. Tel: +1 404 639 6245. (rsiu0@cdc.gov)

Abstract
Introduction: HIV testing is an essential prerequisite for accessing treatment with antiretroviral therapy or prevention using pre-exposure prophylaxis. Internet distribution of HIV self-tests is a novel approach, and data on the programmatic cost of this approach are limited. We analyse the costs and cost-effectiveness of a self-testing programme.

Methods: Men who have sex with men (MSM) reporting unknown or negative HIV status were enrolled from March to August 2015 into a 12-month trial of HIV self-testing in the United States. Participants were randomly assigned either to the self-testing arm or the control arm. All participants received information on HIV testing services and locations in their community. Self-testing participants received up to four self-tests each quarter, which they could use themselves or distribute to their social network associates. Quarterly follow-up surveys collected testing outcomes, including number of tests used and new HIV diagnoses. Using trial expenditure data, we estimated the cost of implementing a self-testing programme. Primary outcomes of this analysis included total programme implementation costs, cost per self-test completed, cost per person tested, and incremental cost per new HIV diagnosis among those self-tested and cost per quality adjusted life year (QALY) saved.

Results: A total of 2665 men were assigned either to the self-testing arm (n = 1325) or the control arm (n = 1340). HIV testing was reported by 971 self-testing participants who completed a total of 5368 tests. In the control arm, 619 participants completed 1463 HIV tests. The self-testing participants additionally distributed 2864 self-tests to 2152 social network associates. Testing during the trial identified 59 participants and social network associates with newly diagnosed HIV infection in the self-testing arm; 11 control participants were newly diagnosed with HIV. The implementation cost of the HIV self-testing programme was $449,510. The cost per self-test completed, cost per person tested at least once, and incremental cost per new HIV diagnosis was $61, $145 and $9365 respectively. We estimated that self-testing programme potentially averted 3.34 transmissions, saved 14.86 QALYs and nearly $1.6 million lifetime HIV treatment costs.

Conclusions: The HIV self-testing programme identified persons with newly diagnosed HIV infection at low cost, and the programme is cost saving.

Keywords: HIV self-testing; social networks; costs and cost-effectiveness; costing methods; clinical trial expenditures; United States

Additional information may be found under the Supporting Information tab for this article.

Received 10 July 2019; Accepted 4 December 2019

Copyright © 2020 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

1 | INTRODUCTION

An estimated 1.1 million people in the United States are living with HIV, and 14% are unaware of their HIV-positive status [1]. Gay, bisexual and other men who have sex with men (MSM) have a higher HIV prevalence, incidence and number of undiagnosed infections than any other group [2]. Surveillance data from the Centers for Disease Control and Prevention (CDC) show that HIV incidence decreased in the overall U.S. population in recent years, but incidence among MSM remained constant or increased among some age groups, including men aged 25 to 34 years and ≥55 years, and one racial/ethnic group, Hispanic MSM [2]. The estimated percentage of HIV infections that were undiagnosed in 2016 was high among MSM overall (16.4%), and especially among Asian (20.5%), Hispanic (20.2%) and African American (19.2%) MSM [1].
Identifying HIV infections through HIV testing is the critical first step in moving persons with HIV into the HIV care continuum, including treatment and viral suppression that enhance survival and quality of life, and prevent HIV transmission [3–6]. The CDC recommends that all sexually active MSM be screened for HIV at least annually, and that clinicians should consider the potential benefits of more frequent screening (e.g., every three or six months) based on their patients’ individual risk factors and local HIV epidemiology and policies [7]. The CDC’s 2016 nonclinical testing guidelines suggested the use of novel testing strategies, such as HIV self-testing [8]. HIV self-testing can reduce barriers to testing and potentially be delivered at low cost [8,9].

In 2012, the U.S. Food and Drug Administration (FDA) approved the first HIV self-test for use in the United States, the OraQuick In-Home HIV Test (OraQuick; OraSure Technologies, Inc.), a rapid test that provides results in 20 minutes [10]. Although HIV self-testing is relatively new in the United States, it has generated increasing interest worldwide [11,12]. The World Health Organization strongly recommended that HIV self-testing be offered as an additional approach to clinical and targeted HIV testing services [11]. In the United States, MSM reported a high willingness to use HIV self-tests [13,14], and using self-tests results in increased screening and awareness of HIV status [14,15]. However, the cost-effectiveness of this strategy for MSM has not been established.

To assess the feasibility and potential benefits of HIV self-testing among MSM, CDC sponsored a nationwide randomized controlled trial (RCT), Evaluation of Rapid HIV Self-Testing among MSM Project (eSTAMP: NCT02067039), in the United States [13,15]. In this analysis, we use trial expenditure data to estimate the cost and cost-effectiveness of delivering a self-testing programme, potentially by a health department or community-based organization, in a non-research setting [16–19]. Although the testing would be performed by participants, a self-testing programme would likely require an organization to conduct recruitment, ship test kits, and collect and report data.

2 | METHODS

2.1 | Study design and participants

The eSTAMP project investigators provided detailed expenditure data on the trial in the United States, including the development and implementation phases, which began in October 2014 and ended in September 2016 (Tables S1 and S2). Trial implementation began with the recruitment of participants who resided in the United States from March through August 2015 via banner advertisements placed on internet sites, including Facebook, other social network sites, and music and dating sites serving MSM. Eligible participants who reported never having been diagnosed with HIV infection were enrolled in the 12-month longitudinal study. Study participants randomly assigned to the self-testing arm were sent by FedEx four HIV self-tests (2 OraQuick oral fluid tests; 2 SURE CHECK HIV 1/2 Assay (Sure Check; Chembio Diagnostics System, Inc.) finger-stick blood tests). Participants could request up to four additional self-tests to replace the ones they had used or given away, after completing each of the follow-up online surveys at three, six and nine months. Participants could use the self-tests or distribute them to their social network associates, for example, friends or sexual partners. The participants could report their self-test results online through the study website or by phone. A participant who reported a preliminary positive self-test result was considered to have a new diagnosis unless subsequent, confirmatory testing indicated a false-positive result [15]. All study participants and social network associates who used the study HIV self-tests were able to call a toll-free hotline to talk with a counsellor from 9 AM to 5 PM Eastern Time, Monday–Friday, and a toll-free crisis line after-hours and on weekends. The eSTAMP study website included a link to AIDSVu.org, where all study participants and social network associates who used the study HIV self-tests could locate information on local HIV testing services in the community. Participants assigned to the control arm were given access to the eSTAMP website with a link to AIDSVu.org and they were not given self-tests by the eSTAMP study. Details on the trial protocol are reported elsewhere [15].

2.2 | Costs and cost-effectiveness analysis

We used two steps to estimate self-testing programme implementation costs over 12-month period, based on invoices from the trial implementation phase. Full trial expenditures, including those for development and implementation, are reported in Table S1. First, we identified the types of resources from the trial implementation likely to be part of the testing strategy’s actual programme implementation. Second, we estimated the fraction of the expenditures for those resources that would be required in the implementation (i.e. excluding research costs). Co-authors involved in the trial as Project Officers (RM, PC), Principal Investigator (PS) and Project Manager (MN) generated the estimates for both steps. Based on the number and scope of activities expected to be associated with programme implementation, we developed a total economic cost of the programme and, within total costs, we estimated fixed (likely to be incurred regardless of the number of participants) and variable (likely to increase or decrease according to the number of participants) costs. The fixed costs included internet site design and monitoring for participants recruitment, programme administration, and office overhead, and the variable costs included HIV test kits, mailing test kits and supplies, and incentives to participants. We excluded the costs related to research and development.

Based on the total programme implementation cost, we estimated the average cost per test completed, cost per person tested and the incremental cost per new HIV diagnosis. We calculated costs per outcome by dividing the total cost by the number of self-tests completed (assuming that all self-tests distributed to social network members were used), by the number of persons (participants and social network members) who completed at least one self-test, and by the number of new HIV diagnoses over and above those in the control arm. We assumed that all costs associated with the self-testing programme were in addition to the costs of standard-of-care HIV testing services received by control participants.

Using the additional new HIV diagnoses identified under self-testing arm, we estimated the incremental number of HIV transmissions averted, lifetime HIV treatment costs saved, QALYs saved and cost per QALY saved [20–22]. We assumed a reduction in transmission per new HIV diagnosis (0.0696),
based a lower HIV transmission rate (0.0516) attributable to MSM being aware of their HIV status compared with those unaware of their status (0.1212) [23]. We applied 4.45 quality adjusted life years (QALYs) saved per infection averted, based on the patients who were diagnosed and entered HIV care at a CD4 count of 500 cells/mL or above [5]. We assumed the lifetime HIV treatment cost to be $466,000 per infection averted [5], and cost-effectiveness threshold to be $100,000, commonly used in the cost-effectiveness analysis in the United States [24–26].

We estimated costs and cost-effectiveness of the self-testing programme from a health care provider’s perspective since we did not measure participant-related costs [16,27,28]. Costs are reported in 2016 U.S. dollars.

### 2.3 Sensitivity analysis

We conducted sensitivity analyses on costs and outcomes to explore how our cost-effectiveness findings might change under different assumptions about programme services and outcomes.

| Table 1. Health outcomes and costs of HIV self-testing programme based on a randomized controlled trial, 2015 to 2016 |
|---------------------------------------------------------------|
| **Participants**                                              |
| Participants enrolled in the trial                           | 1325  | 1340 |
| Participants completing at least 1 follow-up survey          | 1014  | 977  |
| Participants completing any HIV testa                        | 971   | 619  |
| Participants completing HIV self-test                        | 938   | –    |
| No. of all HIV tests reported by participants                | 5368  | 1463 |
| No. of HIV self-tests reported by participants               | 4504  | –    |
| Participants with new HIV diagnosis                          | 25    | 11   |
| **Social network associates**                                |
| No. of self-tests distributed to social network associates    | 2864  | –    |
| Social network associates using self-tests                   | 2152  | –    |
| Social network associates with new HIV diagnosis             | 34    | –    |
| No. of additional new HIV diagnoses under self-testing arm (N)| 48    | –    |
| **Programme costsb**                                         |
| Total cost (C)                                                | $449,510 | – |
| Cost per self-test completedc                                 | $61   | –    |
| Cost per person testedc                                       | $145  | –    |
| **Incremental cost-effectivenessd**                          |
| Transmissions averted per new HIV diagnosis (t)e             | 0.0696| –    |
| QALYs saved per transmission averted (Q)f                    | 4.4500| –    |
| No. of transmissions averted (A = tN)                        | 3.34  | –    |
| No. of QALYs saved (AQ)                                      | 14.86 | –    |
| Lifetime HIV treatment cost saved per transmission averted (T)g| $466,000 | – |
| Total lifetime treatment cost saved (AT)                     | $1,556,454 | – |
| Cost per new HIV diagnosis (C/N)                             | $9365 | –    |
| Cost per HIV transmission averted (C/A)                      | $134,583 | – |
| Cost per QALY saved (C-AT)/AQh                               | ($74,476) | – |

*Included two participants who reported their HIV diagnoses by telephone; **costs exclusively related to research and development were excluded. Costs are reported in 2016 U.S. dollars; *average cost per self-test completed was calculated by dividing the total programme cost by the number of self-tests completed by the participants (n = 4504) and their social network associates (n = 2864), and assumed all self-tests distributed to the associates were used. The cost per person tested was calculated by dividing the total programme cost by the number of participants completing self-test (938) and the associates using self-tests (2152); **incremental cost-effective ratios (ICER) defined as, cost per new diagnosis (C/N), cost per HIV transmission averted (C/A), and cost per QALY saved = [(C-AT)/AQ] ≤ $100,000, where C is total programme cost, N is additional new HIV diagnoses, A is no. of transmissions averted, T is lifetime HIV treatment cost saved per transmission averted, and Q is no. of quality adjusted life years (QALYs) saved per transmission averted [21–23]; all costs and health outcomes are additional to those of the controlled arm. Threshold for cost-effectiveness assumed to be $100,000 [24–26]. Cost saving threshold: ICER = [(C–AT)/AQ] < 0, or (C–AT) < 0, or C < AT; **transmissions averted per new HIV diagnosis (t, 0.0696) is based on the estimated transmissions attributable to MSM aware of their HIV status (0.0516) compared with those unaware of their status (0.1212) [23]; **QALYs saved per transmission averted (Q) is based on the patients diagnosed and entered HIV care at a CD4 count of 500 cells/mL or above [5]; **lifetime treatment cost saved per HIV transmission averted (T) based on the patients diagnosed and entered HIV care at a CD4 count of 500 cells/mL or above, discounted at 3% [5], and adjusted to 2016 US dollars; **result in parentheses shows a negative ICER, indicating the programme is cost saving to the health care provider, that is, the self-testing programme cost (C) was less than the cost of estimated HIV transmissions averted by the programme (AT). The cost per new diagnosis can be as high as $32,400 (i.e. $1,556,500/48) for cost saving threshold, and $63,400 for cost-effectiveness, at $100,000 cost per QALY threshold.
the length of the programme. First, we streamlined the fixed
costs by assuming that the self-testing programme could be
an addition to HIV testing services already being provided by
the agency, thus generating only minimal additional fixed costs.
For instance, we halved the time required for project adminis-
tration, to approximate the time a project manager would
actually spend delivering the self-testing programme. Further-
more, we excluded office space and overhead costs while
retaining participant recruitment and monitoring costs and all
variable costs. Second, we shortened the programme duration
to six and three months, instead of 12. For this analysis, we
assumed that recruitment and monitoring costs would remain
the same as in the base case, but that other fixed and variable
costs would be incurred only for the length of the interven-
tion. Third, we explored cost-effectiveness when the number
of new diagnoses associated with self-testing in a given time-
frame increased and decreased.

The trial was approved by the Institutional Review Board at
Emory University, Atlanta, Georgia. Sure Check was used
under an Investigational Device Exemption from the FDA. All
participants provided separate online consent for screening
and participation in the study, and they could voluntarily with-
draw during the study.

Table 2. HIV self-testing programme costs and required resources based on a randomized controlled trial, 2015 to 2016

| HIV self-testing programme cost ($\text{a}) | Distribution of cost (%) |
|------------------------------------------|--------------------------|
| Fixed costs                              |                          |
| Internet site design and monitoring      |                          |
| Internet site design and monitoring      | 33,060                   | 7.4%                      |
| Online advertising and recruitment       | 11,221                   | 2.5%                      |
| Administration                          |                          |
| Project director/supervisor              | 543                      | 0.1%                      |
| Project manager                         | 45,036                   | 10.0%                     |
| Administrative manager                  | 475                      | 0.1%                      |
| Data analysts                            | 11,190                   | 2.5%                      |
| Data cleaning and management             | 6978                     | 1.6%                      |
| Internet technology security specialist   | 4489                     | 1.0%                      |
| Clerical – Test kits shipping and handling| 40,480                   | 9.0%                      |
| Office overhead                          |                          |
| Office space (39.09% of labour cost)     | 43,676                   | 9.7%                      |
| General and administrative overhead      | 24,734                   | 5.5%                      |
| Sub-total                                | 221,882                  | 49.4%                     |
| Variable costs                           |                          |
| HIV testing kits distribution            |                          |
| HIV test kits (N = 8654, $18.65/test)\text{b} | 161,433               | 35.9%                     |
| Mailing test kits and supplies           | 36,161                   | 8.0%                      |
| Incentives to participants               | 30,034                   | 6.7%                      |
| Sub-total                                | 227,628                  | 50.6%                     |
| Total                                    | 449,510                  | 100.0%                    |

\text{a}Cost refers to the total amount spent during the implementation phase of the trial on activities and resources that the investigators (co-authors: RM, PC, PS, MN) determined would be required in the implementation of a self-testing programme. Costs were reported in 2016 U.S. dollars;
\text{b}Self-test kits included those used by participants (n = 4504) and associates (n = 2864) and those not accounted for (n = 1286). OraQuick in-
home HIV test was approved by the U.S. Food and Drug Administration (FDA) for self-test, and price of the test was negotiated between the pro-
ject contractor and manufacturer, OraSure Technologies, Inc.; Sure Check was used under an Investigational Device Exemption from the FDA, and
cost included the production, shipping and handling.

3 | RESULTS

A total of 2665 men were randomly assigned to either the
self-testing arm (n = 1325) or the control arm (n = 1340,
Table 1) and completed a baseline survey. During the 12-
month trial period, HIV testing was reported by 971 self-test-
ing participants (two of whom did so by calling the study hot-
line only) and 619 control participants. Control participants
reported testing 1463 times and self-testing participants
reported testing 5368 times, of which 4504 were with self-
tests received from the study. The self-testing participants dis-
tributed 2864 self-tests to 2152 social network associates.
Testing during the trial identified 25 new HIV diagnoses
among self-testing participants, 34 new HIV diagnoses among
their social network associates, and 11 new diagnoses among
control participants. Thus, the self-testing arm yielded a total
of 59 new HIV diagnoses among the 3477 persons who
received a study HIV self-test, or 48 more than the control
arm.

We estimated the cost of the HIV self-testing programme
to be $449,510 (Tables 1 and 2). The cost per self-test com-
pleted was $61, and the cost per person completing at least
one self-test was $145. When we subtracted the number of...
|                                   | Persons tested or self-tested | Test kits used | New HIV diagnoses | Trans-missions averted | QALYs saved | Total programme cost ($) | Cost/ self-test ($) | Cost/person tested ($) | Incr. cost/ new diagnosis ($) | Incr. cost/ transmission averted ($) | Incr. cost/ QALY saved ($) |
|-----------------------------------|-------------------------------|----------------|-------------------|------------------------|-------------|--------------------------|---------------------|--------------------------|-------------------------------|----------------------------------|-------------------------------|
| **Twelve-month programme: base case** |                               |                |                   |                        |             |                          |                     |                          |                               |                                 |                               |
| Self-testing arm                  | 3090                          | 7368           | 59                | 334                    | 14.86       | 449,510                  | 61                  | 145                      | 9365                          | 134,583                          | (74,476)                      |
| Control arm                       | 619                           | –              | –                 | –                      | –           | –                        | –                   | –                        | –                              | –                                | –                            |
| **Twelve-month intervention: streamlined testing** |                               |                |                   |                        |             |                          |                     |                          |                               |                                 |                               |
| Self-testing arm                  | 3090                          | 7368           | 59                | 334                    | 14.86       | 316,945                  | 43                  | 103                      | 6603                          | 94,893                           | (83,395)                      |
| Control arm                       | 619                           | –              | –                 | –                      | –           | –                        | –                   | –                        | –                              | –                                | –                            |
| **Six-month intervention**        |                               |                |                   |                        |             |                          |                     |                          |                               |                                 |                               |
| Self-testing arm                  | 2044                          | 7061           | 34                | 237                    | 10.53       | 349,932                  | 50                  | 171                      | 11,288                        | 147,909                          | (71,481)                      |
| Control arm                       | 452                           | –              | –                 | –                      | –           | –                        | –                   | –                        | –                              | –                                | –                            |
| **Three-month intervention**      |                               |                |                   |                        |             |                          |                     |                          |                               |                                 |                               |
| Self-testing arm                  | 1431                          | 6462           | 23                | 160                    | 7.12        | 285,976                  | 44                  | 200                      | 13,618                        | 178,687                          | (64,565)                      |
| Control arm                       | 284                           | –              | –                 | –                      | –           | –                        | –                   | –                        | –                              | –                                | –                            |

*Number of persons tested under the self-testing arm (n = 3090) included the participants (n = 938) and associates (n = 2152) completing HIV self-tests. The number of self-tests (n = 7368) used included the tests used by participants (n = 4504) and associates (n = 2864). Of the total tests distributed (N = 8654), 1286 tests were not accounted for. All tests distributed to associates were assumed to have been used and, thus, all associates were assumed to have self-tested at least once; six- and three-month programmes included full recruitment and monitoring costs, but included fixed costs incurred only for the length of the intervention and variable costs based on the number of participants served during the intervention. While the length of these scenarios was assumed, self-testing outcomes were based on actual data from the eSTAMP intervention; transmissions averted calculation is based on the estimated transmissions attributable to MSM aware of their HIV status (0.0516) compared with those unaware of their status (0.1212) [23], thus the difference is transmissions averted per new HIV diagnosis (0.0696). QALYs saved per transmission averted is based on the patients diagnosed and entered HIV care at a CD4 count of 500 cells/mL or above [5]; cost per self-test completed in six- and three-month programmes were lower compared to the base case, partly because of the relatively larger number of tests distributed during those periods; incr. is incremental, and incremental cost-effective ratios (ICER) defined as, cost per new diagnosis (C/N), cost per HIV transmission averted (C/A), and cost per QALY saved (C-AT)/AQ ≤ $100,000, where C is total programme cost, N is additional new HIV diagnoses, A is no. of transmissions averted, T is lifetime HIV treatment cost saved per transmission averted, and Q is no. of quality adjusted life years (QALYs) saved per transmission averted [21–23]; streamlined self-testing programme excluded fixed costs, except participant recruitment and monitoring, and halved the project administration time.
new diagnoses in the control arm from the new HIV diagnoses in the self-testing arm, the incremental cost per new diagnosis (or incremental cost-effectiveness ratio, ICER) was $9365. We estimated that the self-testing programme averted 3.34 HIV transmissions, and saved 14.86 QALYs and $1,556,454 lifetime HIV treatment costs, much higher than the total programme cost ($449,510, Table 1), suggesting that the self-testing programme was cost saving.

In our analysis, the key programme implementation resources identified are listed in Table 2. The fraction of the trial implementation expenditure that a programme would be expected to incur ranged from 0.05 (administrative manager) to 1.00 (e.g. test kits, N = 8654) of the trial implementation expenditures (Table S1). The distribution of the costs across programme activities showed that approximately half of the total costs were variable (Table 2). Among the fixed costs was recruitment of participants through online venues. Online dating and internet radio sites recruited the majority (95%) of the participants, and the cost per participant completing a baseline interview ranged from $2 to $123, depending on the recruitment site (Table S3).

In sensitivity analysis, when we assumed streamlined testing and reduced the fixed costs but included all variable costs in the analysis, the total annual programme cost decreased by 29% from the base case. The resulting average cost per self-test completed, cost per person tested, and incremental cost per new diagnosis were estimated to be $43, $103 and $6603 (Table 3). We assumed the same number of new HIV diagnoses under streamlined testing as in the base case. Thus, the line showing relationship between new diagnoses and costs shifted down from the base case (Figure 1). When we reduced the programme length to six months and three months, the total cost decreased by 22% and 36% respectively, and the resulting average cost per self-test completed, cost per person tested, and incremental cost per new diagnosis were $50 and $44, $171 and $200, and $11,288 and $13,618 respectively. These costs were based on the actual number of participants and associates who self-tested and were diagnosed in the six- and three-month periods: 2044 (34 new diagnoses) and 1431 (23 new diagnoses) respectively. In each of these sensitivity analyses, the programme remained cost saving.

![Figure 1. Relationship between incremental cost and new HIV diagnoses in self-testing intervention.](https://example.com/figure1.png)

4 | DISCUSSION

We estimated the total cost of the HIV self-testing programme to be $449,510 with the programme reaching and providing self-tests to 3477 persons (participants and social network associates). The average cost per self-test completed, cost per person tested and incremental cost per new HIV diagnosis were $61, $145 and $9365 respectively. The self-testing programme averted 3.34 HIV transmissions, and saved 14.86 QALYs and nearly $1.6 million lifetime HIV treatment costs. Thus, the programme was cost saving. Cost analysis of HIV testing in various health care and non-health care settings under the CDC’s Advancing HIV Prevention project showed that the cost per new HIV diagnosis ranged from $3500 to $36,300 ($US 2016) [29]. Similarly, the cost analysis of the Expanded Testing Initiative showed that the cost per new HIV diagnosis ranged from $6100 to $73,600 ($US 2016) [30]. Cost-effectiveness modelling of HIV testing interventions that incorporated longer-term costs and health consequences, such as lifetime HIV treatment costs and quality-adjusted life-years (QALYs), suggests that the cost per new HIV diagnosis can be as high as $28,300 ($US 2016) and remain cost saving [22]. Our analysis shows that the cost per new diagnosis can be as high as $32,400 for the self-testing programme to remain cost saving and $63,400 to remain cost effective, at $100,000 cost per QALY threshold.

The low cost per new HIV diagnosis of the self-testing programme is related to the number of newly diagnosed infections reported among self-testing participants and social network associates (n = 59). Furthermore, even participants in the control arm had reported positive test results that were considered newly diagnosed infections (n = 11) given that they started the RCT as HIV negative or HIV unknown. This suggests that the internet-based recruitment strategies used in the trial were successful in reaching persons at risk of HIV infection and engaging them in testing. The number of infections among persons who received a self-test (59/3477, 1.7%) is much higher than those detected in recent large-scale HIV testing programmes implemented by health departments in health care (median, 0.3%) and non-health care (median, 0.6%) settings [31], and higher or within the range reported in HIV screening programmes in jails (0.2% to 1.3%) [32–34] and targeted HIV testing programmes implemented by community-based organizations in outreach settings (0.7% to 2.2%) [35,36].

Our analysis showed a relatively high proportion of fixed costs (50% of the total) in the self-testing programme, which is common in other HIV testing programmes [16,29,35]. We explored the potential impact of reduced fixed costs by streamlining the self-testing programme, and when we did so, the total annual programme cost decreased by 29% from the base case, suggesting that there may be room for greater programme efficiencies. Furthermore, self-testing programmes may be able to reduce fixed or variable costs by collaborating with test manufacturers for delivery of some of the services, including direct shipping of rapid self-test kits to participants. The New York City Health Department has already initiated such a collaborative programme with manufacturers [37]. We also explored the impact of shorter programme periods (six and three months). The results showed that the average cost per person tested and incremental cost per new HIV diagnosis...
(i.e. ICER) might increase with shorter programme periods; however, the ICERs were still much lower than the cost saving threshold [20].

Prior research documents a willingness to self-test [13,38,39]. Nunn and colleagues showed that among the participants surveyed in predominantly African American U.S. neighbourhoods with 3% HIV prevalence, nearly 90% were likely or very likely to accept a free HIV self-test, and 55% were willing to purchase a test; however, only 23% were willing to pay the market price ($40/test) [38]. Therefore, public sector funding may be critical for the adoption of HIV self-testing among high-risk populations.

4.1 | Limitations

Limitations of our study include that we conducted the cost analysis retrospectively based on trial expenditures reported to the CDC. Hence, the initial cost data reflected expenditures inclusive of research and development costs. Although we developed a systematic approach to estimate the cost of the implementation of a self-testing programme exclusive of research and development costs, we may have under- or over-estimated actual implementation costs.

Second, all HIV self-testing and clinic based testing information was based on participants’ reporting their HIV test results online or by phone to study staff. We assumed the reported HIV-positive test result was a new diagnosis unless subsequent, confirmatory testing indicated a false-positive result [15]. We were unable to confirm all reported positive test results; thus the number of new HIV diagnoses in our analysis could be lower and the ICER higher than those reported in the base case (Figure 1). In addition, some studies have found that only about 50% to 60% of positive HIV tests reflect new diagnoses [40–42]. However, all eSTAMP participants reported never having been diagnosed with HIV and 17% reported never having been tested for HIV [15], reducing the likelihood of a previous diagnosis.

Third, the average cost of an HIV test kit was $18.65 in our analysis. The price of OraQuick in-home HIV test, the FDA approved self-test, was negotiated between the project contractor and manufacturer (OraSure Technologies, Inc.). Sure Check was used under an investigational device exemption from the FDA, and the cost included the production of the device, shipping and handling. If an organization implementing a HIV self-testing programme were required to pay higher price than the price used in our analysis, ICER would be higher and self-testing programme would be less cost-effective.

Fourth, some study participants may have been unwilling to disclose their positive test results. The eSTAMP trial did not receive any follow-up information from 25% of the participants who were mailed the HIV self-testing kits after completing the baseline survey [15]. If more HIV infections were diagnosed than reported, the ICER could be lower, making the self-testing programme even more cost-effective (Figure 1).

5 | CONCLUSIONS

We estimated the costs and cost-effectiveness of a rapid HIV self-testing programme based on the expenditure data reported by a randomized controlled trial in the United States. Our analysis showed the potential for an HIV self-testing programme to be cost saving in the base case and under several scenarios. Making HIV testing simple, accessible, and routine, and increasing the number of people who know their diagnosis is key to preventing HIV transmission and supports the recently announced U.S. initiative, “Ending the HIV Epidemic: A Plan for America” [6]. HIV self-testing, through internet recruitment and the distribution of tests by mail, could be a promising new strategy to reach more at-risk persons at a relatively low cost. A self-testing programme also could serve those who cannot or will not access traditional HIV testing services.

AUTHORS’ AFFILIATIONS

1. Centers for Disease Control and Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Atlanta, GA, USA; 2. Evidence Solutions Group, Hayes Inc., Dallas, TX, USA; 3. Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA

COMPETING INTERESTS

The authors declare no competing interests.

AUTHORS’ CONTRIBUTIONS

All authors contributed to the conceptualization of the paper. RK Shrestha, RJ MacGowan and PR Chavez wrote the first draft of the paper. SL Sansom, JH Mermin, PS Sullivan and M Nobell contributed to subsequent drafts of the paper. RJ MacGowan, PR Chavez and RK Shrestha had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. All authors approved the final draft of the paper.

ACKNOWLEDGEMENT

We acknowledge the contributions of the eSTAMP Study Group (Mary Ann Chaisson, Steven Ethebrede, Arin Freeman, Laura Gravens, Darrel Higa, Sabina Hirshfield, Wayne Johnson, AD McNaghten, Brian Mustanski, Jerris Raiford, Akshay Sharma, Laura Wesolowski) in designing and implementing the study.

FUNDING

This research was funded by CDC under contract 200-2011-41989. The funding source had no role in the design and conduct of the study; data collection, analysis, reporting; and decision to submit the manuscript for publication.

DISCLAIMER

The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention.

REFERENCES

1. Centers for Disease Control and Prevention. Estimated HIV incidence and prevalence in the United States, 2010–2016. HIV Surveillance Supplemental Report 2019;24 (No. 1). 2019. [cited 2019 Mar 5]. Available from: http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html
2. Singh S, Song R, Johnson AS, McCray E, Hall HI. HIV incidence, prevalence, and undiagnosed infections in U.S. men who have sex with men. Ann Intern Med. 2018;168(10):685–94.
3. Centers for Disease Control and Prevention. Vital signs: HIV prevention through care and treatment—United States. MMWR Morb Mortal Wkly Rep. 2011;60(47):1618–23.
4. White House Office of National AIDS Policy. National HIV/AIDS strategy for the United States: updated to 2020. Washington, DC: The White House Office of National AIDS Policy [cited 2019 Nov 13]. 2015. Available from: https://files.hiv.gov/f3r/public/nhas-update.pdf
5. Farnham PG, Gopalappa C, Sansom SL, Hutchinson AB, Brooks JT, Weidle PJ, et al. Updates of lifetime costs of care and quality-of-life estimates for HIV-infected persons in the United States: late versus early diagnosis and entry into care. J Acquir Immune Defic Syndr. 2013;64(2):183–9.
Shrestha RK et al. Journal of the International AIDS Society 2020; 23:e25445
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25445/full | https://doi.org/10.1002/jia2.25445

6. U.S. Department of Health & Human Services. Ending the HIV epidemic: a plan for America. U.S. Department of Health & Human Services [cited 2019 Mar 6]. February 5, 2019. Available from: https://www.hhs.gov/blog/2019/02/05/ending-the-hiv-epidemic-a-plan-for-america.html

7. DiNenno EA, Prejean J, Irwin K, Delaney KP, Bowles K, Martin T, et al. Recommendations for HIV screening of gay, bisexual, and other men who have sex with men - United States, 2017. MMWR Mortal Wkly Rep. 2017;66(31):830–2.

8. Centers for Disease Control and Prevention. Implementing HIV testing in nondiagnostic settings: a guide for HIV testing providers. HIV Surveillance Supplemental Report. 2012. 2017 [Aug 3]. Available from: https://www.cdc.gov/hiv/testing/nondiagnostic/index.html

9. Linas BP. Potential impact and cost-effectiveness of self-testing for HIV in low-income countries. J Infect Dis. 2015;212(4):513–5.

10. Food and Drug Administration. Home HIV Test Kit. U.S. Food and Drug Administration. [cited 2018 Aug 2]. Available from: https://www.fda.gov/BiologicsBloodVaccines/BloodBloodProduct/ApprovedProducts/PremarketApprovalPMAs/ucm310436.htm

11. World Health Organization. Guidelines on HIV self-testing and partner notification: supplement to consolidated guidelines on HIV testing services. Geneva: World Health Organization; 2016 [2018 Aug 2]. Available from: http://www.who.int/hiv/pub/vct/hiv-self-testing-guidelines/en/

12. Stevens DR, Vrana CJ, Dinl RE, Korte JE. A Global review of HIV self-testing: themes and implications. AIDS Behav. 2018;22(2):497–512.

13. Sharma A, Chavez PR, MacGowan RJ, McNaghten AD, Mustanski B, Gravesen L, et al. Willingness to distribute free rapid home HIV test kits and to test with social or sexual network associates among men who have sex with men in the United States. AIDS Care. 2017;29(12):1499–503.

14. Katz DA, Golden MR, Hughes JP, Farquhar C, Stekler JD. HIV self-testing increases HIV testing frequency in high-risk men who have sex with men: a randomized controlled trial. J Acquir Immune Defic Syndr. 2018;78(5):505–12.

15. MacGowan RJ, Chavez PR, Borkowf CB, Owen SM, Calhoun CB, et al. Effect of internet-distributed HIV self-tests on HIV diagnosis and behavioral outcomes in men who have sex with men: a randomized clinical trial. JAMA Intern Med. 2019;180(1):117–125. https://doi.org/10.1001/jamainternmed.2019.5222

16. Ruger JP, Ben Abdallah A, Cotter L. Costs of HIV prevention among out-of-treatment drug users: results of a randomized controlled trial. Public Health Rep. 2010;125 Suppl 1:83–94.

17. Shrestha RK, Gardner L, Marks G, Caw J, Malitz F, Giordano TP, et al. Estimating the cost of increasing retention in care for HIV-infected patients: results of the CDC/HRSA retention in care trial. J Acquir Immune Defic Syndr. 2015;68(3):345–50.

18. Haddix AC, Teutsch SM, Corso PS. Prevention effectiveness: a guide to decision analysis and economic evaluation. New York: Oxford University Press, 2003.

19. Ramsey S, Willke R, Briggs A, Brown R, Buxton M, Chawla A, et al. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT–CEA Task Force report. Value Health. 2005;8(5):521–33.

20. Pinkerton SD, Holtgrave DR. A method for evaluating the economic efficiency of HIV behavioral risk. AIDS Behav. 1998;2(3):189–201.

21. Pinkerton SD, Holtgrave DR, Jemmott JB 3rd. Economic evaluation of HIV risk reduction intervention in African-American male adolescents. J Acquir Immune Defic Syndr. 2000;25(2):164–72.

22. Farnham PG, Sansom SL, Hutchinson AB. How much should we pay for a new HIV diagnosis? A mathematical model of HIV screening in US clinical settings. Med Decis Making. 2012;32(3):459–69.

23. Lin F, Farnham PG, Shrestha RK, Mermin J, Sansom SL. Cost effectiveness of HIV prevention interventions in the US. Am J Prev Med. 2016;50(6):699–708.

24. Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness—the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9):796–7.

25. Schickman BR, Metts LR, Colfax GN, Jeff A, Wong A, Scott CA, et al. The cost-effectiveness of rapid HIV testing in substance abuse treatment: results of a randomized trial. Drug Alcohol Depend. 2013;128(1–2):90–7.

26. Gopalappa C, Farnham PG, Hutchinson AB, Sansom SL. Cost effectiveness of the National HIV/AIDS Strategy goal of increasing linkage to care for HIV-infected persons. J Acquir Immune Defic Syndr. 2012;61(1):99–105.

27. Neumann PJ, Ganiats TG, Russell LB, Sanders GD, Siegel JE. Cost-effectiveness in health and medicine, 2nd edn. New York: Oxford University Press, 2017.

28. Pinkerton SD, Martin JN, Roland ME, Katz MH, Coates TJ, Kahn JO. Cost-effectiveness of postexposure prophylaxis after sexual or injection-drug exposure to human immunodeficiency virus. Arch Intern Med. 2004;164(1):46–54.

29. Shrestha RK, Sansom SL, Farnham PG. Comparison of methods for estimating the cost of human immunodeficiency virus-testing interventions. J Public Health Manag Pract. 2012;18(3):259–67.

30. Shrestha RK, Duffy N, Farnham PG & Sansom SL. Estimating comprehensive expenditure of large-scale HIV testing interventions in the United States. Presented in American Society of Health Economists, Minneapolis, MN, 2012.

31. Rao S, Zhao H, Heitgerd J, Belcher L & Lyles C. Cost for HIV testing and identifying newly diagnosed HIV-positive persons in health care and non-health care settings, 2015. Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention. Atlanta, GA; 2018.

32. Shrestha RK, Sansom SL, Richardson-Moore A, French PT, Scalco B, Lalota M, et al. Costs of voluntary rapid HIV testing and counselling in jails in 4 states—advancing HIV Prevention Demonstration Project, 2003–2006. Sex Trans Dis. 2009;36:25–55.

33. Macgowan R, Margolis A, Richardson-Moore A, Wang T, Lalota M, French PT, et al. Voluntary rapid human immunodeficiency virus (HIV) testing in jails. Sex Transm Dis. 2009;36:2 Suppl 59–13.

34. Centers for Disease, C. and Prevention. Routine HIV screening during intake medical evaluation at a County Jail - Fulton County, Georgia, 2011-2012. MMWR Mortal Wkly Rep. 2013;62(24):495-7.

35. Shrestha RK, Clark HA, Sansom SL, Song B, Buckendahl H, Calhoun CB, et al. Cost-effectiveness of finding new HIV diagnoses using rapid HIV testing in community-based organizations. Public Health Rep. 2008;123 Suppl 3:94–100.

36. Clark HA, Bowles KE, Song B, Heffelfinger JD. Implementation of rapid HIV testing programs in community and outreach settings: perspectives from staff at eight community-based organizations in seven U.S. cities. Public Health Rep. 2008;123 Suppl 2:86–93.

37. Edelstein A. Feasibility and Reach of a HIV Self-Test (HIVST) Giveaway, New York City, 2015–16. Conference on Retrosviruses and Opportunistic Infections (CROI). Seattle, WA; February 13–16, [cited 2019 Mar 6]. 2017. Available from: http://www.croiconference.org/sites/default/files/uploads/croi2017-abstract-eBook.pdf

38. Nunn A, Brinkley-Rubinstein L, Rose J, Mayer K, Stopka T, Towey C, et al. Latent class analysis of acceptability and willingness to pay for self-HIV testing in a United States urban neighbourhood with high rates of HIV infection. J Int AIDS Soc. 2017;20(1):21290.

39. Myers JE, El-Sadr Davis OY, Weinstein ER, Remch M, Edelstein A, Khawja A, et al. Availability, accessibility, and price of rapid HIV self-tests. New York city pharmacies, summer 2013. AIDS Behav. 2017;21(2):515–24.

40. Centers for Disease, C. and Prevention. Previous HIV testing among adults and adolescents newly diagnosed with HIV infection - National HIV Surveillance System, 18 jurisdictions, United States, 2006-2009. MMWR Mortal Wkly Rep. 2012;61(24):441-5.

41. Hanna DB, Tsoi BW, Begier EM. Most positive HIV western blot tests do not diagnose new cases in New York City: implications for HIV testing programs. J Acquir Immune Defic Syndr. 2009;51(5):609–14.

42. Hoots BE, Wejnert C, Martin A, Haerland R, Masciotra S, Sionean C, et al. Undisclosed HIV infection among MSM in a behavioral surveillance study. AIDS. 2017;31(5):830–6.

SUPPORTING INFORMATION

Additional information may be found under the Supporting Information tab for this article.

Table S1. eSTAMP trial expenditures and estimated costs of the self-testing programme, 2015 to 2016.

Table S2. eSTAMP trial staff time and allocation of labour hours to the self-testing programme, 2015 to 2016.

Table S3. Advertising and recruitment cost of the an HIV self-testing programme based on a randomized controlled trial, 2015 to 2016.